MET and breast carcinoma: In invasive cancer, cMET overexpression is seen in metastatic tumours and the amino acid transporter SLC7A5 is a component of the MammaStratTM signature and more recently shown to be a key therapeutic target in ER+ breast cancer.40 These data support the relevance of cMET and SLC7A5 proteins in the biology of breast cancer.